<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102703">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02132260</url>
  </required_header>
  <id_info>
    <org_study_id>NFTC 1301</org_study_id>
    <nct_id>NCT02132260</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Evaluate the Safety and Efficacy of a Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.) and the Naftin® (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC) in Patients With Tinea Pedis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the efficacy and safety of the test formulation of
      Naftifine Hydrochloride Cream 2% to Naftin® (Naftifine Hydrochloride) 2% Cream in a 6 week
      study in patients with tinea pedis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Therapeutic Cure</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of subjects with therapeutic cure (both mycological cure and clinical cure) at the test-of-cure visit conducted four weeks after the end of treatment.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">890</enrollment>
  <condition>Tinea Pedis</condition>
  <arm_group>
    <arm_group_label>Naftifine Hydrochloride Cream 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naftin® (Naftifine Hydrochloride) Cream 2%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naftin® (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Topical Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Topical Cream (Taro Pharmaceuticals Inc.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naftifine Hydrochloride Cream 2%</intervention_name>
    <description>Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.) applied once-daily for two weeks</description>
    <arm_group_label>Naftifine Hydrochloride Cream 2%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naftin® (Naftifine Hydrochloride) Cream 2%</intervention_name>
    <description>Naftin® (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC) applied once-daily for two weeks.</description>
    <arm_group_label>Naftin® (Naftifine Hydrochloride) Cream 2%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Topical Cream</intervention_name>
    <description>Placebo Topical Cream (Taro Pharmaceuticals Inc.) applied once-daily for two weeks.</description>
    <arm_group_label>Placebo Topical Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant, non-lactating females 18 years or older

          -  Clinical diagnosis of tinea pedis with lesions localized to the interdigital spaces
             or predominantly interdigital, but may extend to other areas of the foot

          -  The presence of interdigital tinea pedis infection

          -  The sum of the clinical signs and symptoms scores of the target lesion is at least 4,
             including a minimum score of at least 2 for erythema and a minimum score of 2 for
             either scaling or pruritus

        Exclusion Criteria:

          -  Females who are pregnant, lactating or planning to become pregnant during the study
             period

          -  Use of antipruritics, including antihistamines within 72 hours prior to baseline
             visit

          -  Use of topical corticosteroids, antibiotics or antifungal therapies within two weeks
             prior to baseline visit

          -  Use of systemic corticosteroids, antibiotics or antifungal therapies within one month
             prior to baseline visit

          -  Use of oral terbinafine or itraconazole within two months prior to baseline visit

          -  Use of immunosuppressive medication or radiation therapy within three months prior to
             baseline visit

          -  Any known hypersensitivity to Naftifine Hydrochloride, or any component of the
             formulation

          -  Confluent, diffuse moccasin-type tinea pedis of the entire plantar surface

          -  History of significant or current evidence of chronic infectious disease, system
             disorder, organ disorder, or other medical condition that would place undue risk by
             participation or could jeopardize the integrity of study evaluations

          -  Evidence of any concurrent dermatophytic infection of the toe nails or dermatological
             condition of the foot that may interfere with tinea pedis evaluation

          -  Past history of dermatophyte infections with a lack of response ot antifungal therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>May 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Naftifine</keyword>
  <keyword>Naftin®</keyword>
  <keyword>Tinea pedis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naftifine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
